Meihua International Medical Technologies Co., Ltd.

What they do

The company develops and sells surgical and medical instruments and apparatus through a chain of wholly owned PRC and Hong Kong subsidiaries, including Yangzhou Huada, Jiangsu Yada and Jiangsu Huadong. It also holds a 51% interest in Hainan Ruiying Technology and a 100% interest in Meihua Future Manufacturing Limited in New York. The company reorganized its capital structure in November 2025, splitting its ordinary shares into Class A and Class B ordinary shares.

Revenue drivers

• Medical device sales through PRC operating subsidiaries — Revenue is generated by the PRC subsidiaries Yangzhou Huada, Jiangsu Yada and Jiangsu Huadong, which sell surgical and medical instruments and apparatus, primarily in China.
• Majority-owned Hainan Ruiying Technology — The company holds 51% of Hainan Ruiying, which contributes to consolidated results, though no segment-level revenue figures were disclosed in the excerpt provided.
• New York-based Meihua Future Manufacturing — A 100%-owned New York entity formed as part of the corporate structure; no revenue contribution was disclosed in the filing excerpt.

Recent performance

Revenue fell to $61.8 million in 2025 from $96.9 million in 2024, extending a multi-year decline from $104.0 million in 2021. Net income was $6.8 million in 2025, down from $10.8 million in 2024 and well below the $20.9 million reported in 2021. Operating cash flow was approximately $570 thousand in 2025, compared with $14.6 million in 2024. Diluted EPS was $18.04 in 2025 versus $39.62 in 2024; the large per-share figures reflect the company's very small share count rather than a change in total earnings. Cash and equivalents stood at $15.2 million at December 31, 2025, with total assets of $207.2 million and shareholder equity of $188.9 million.

Strategy

The filing discloses a corporate structure built through wholly owned subsidiaries in Hong Kong and the PRC, plus a wholly owned New York entity, Meihua Future Manufacturing Limited. In November 2025 the company implemented a dual-class share structure with Class A shares at $0.05 par value and Class B shares at $0.05 par value. No forward-looking strategic initiatives, acquisitions or capital investment plans were described in the excerpt provided.

Risks

• Revenue and earnings decline — Revenue fell from $104.0 million in 2021 to $61.8 million in 2025, and net income fell from $20.9 million to $6.8 million over the same period.
• Operating cash flow volatility — Operating cash flow swung from negative $9.2 million in 2022 to $14.6 million in 2024 and back to roughly $570 thousand in 2025, showing limited consistency.
• Limited trading venue — Class A ordinary shares trade on OTC Markets under MHUAF rather than a national securities exchange, which can reduce liquidity and visibility.
• Complex cross-border subsidiary structure — Operations run through Cayman, Hong Kong, PRC and New York entities, including a 51%-owned PRC subsidiary and a dual-class share structure implemented in November 2025, adding governance and consolidation complexity.

Outlook

The excerpt provided does not include management's forward-looking guidance or a stated outlook for fiscal 2026. No specific revenue, margin or capital expenditure targets were disclosed in the material supplied.